COVID-19 pandemisinin meme kanser teşhis sürecine etkisi

Amaç: Bu çalışmada amaç pandemi ve pandemi öncesi döneminde meme lezyonlarının teşhisinde tru-cut biyopsi sayılarının karşılaştırılmasıdır. Gereç ve Yöntem: Bu çalışmada pandemi ve pandemi öncesi donem karşılaştırıldı. Pandemi öncesi dönem, 1 Mart 2018 ve 29 Şubat 2020 arası ve pandemi dönemi ise, 12 Mart 2022 ile 12 Mart 2022 arasında idi. Her dönemde çalışmaya meme kanseri şüphesi lezyonları nedeniyle tru-cut biyopsi yapılan hastalar dahil edildi. Pandemi dönemi ve pandemi öncesi dönemde tru-cut biyopsi yapılan hastaların tru-cut biyopsi sonucunda histopatolojik bulguları ve BI-RADS sonuçları karşılaştırıldı. Bulgular: Pandemi öncesi ve pandemi döneminde yapılan tru-cut biyopsi sayısı benzer idi (1596, 1599). Pandemi döneminde tru-cut biyopsi sonucu histopatolojik raporlar, benign ve yüksek riskli vakaların istatistiksel olarak azaldığını, invaziv karsinom vakalarının ise 1,9 (%95 CI 1,6-2.2) kat arttığını ortaya koydu. Pandemi döneminde ultrasonografi kılavuzluğunda BI-RADS 3 ve BI-RADS 4a vakaları istatistiksel olarak önemli ölçüde azaldı, BI-RADS 4b vakaları 1,4 (%95 GA 1,1-2,2) kat, BI-RADS 4c vakaları 1,7 (%95 CI 1,2 -2,2), BI-RADS 5 vaka 2.1 (%95 CI 1,4-3,1) kat arttı. Sonuç: Pandemi ve pandemi öncesi döneme göre tru-cut biyopsi sayılarında önemli bir değişiklik olmadı. Ancak pandemi döneminde tespit edilen kanserlerin evresi daha yüksekti.

The impact of the COVID-19 pandemic on the breast cancer diagnosis process

Purpose: The primary aim of thşis study was to evaluate difference in the number of patients with tru-cut biopsies to diagnose breast lesions between non-pandemic and pandemic periods. Materials and Methods: In this study, the nonpandemic period and the pandemic period were compared, the periods for the pandemic times, between March 1, 2018, and 29 February 2020, and for the nonpandemic period, 1 March 2020 to 12 March 2022 to 12 March 2022. In each period, we have included all the tru-cut biopsies for suspected breast cancer. During the pandemic and non-pandemic period, the number of tru-cut biopsies BI-RADS and histopathological findings of the patients who experienced tru-cut biopsies were compared. Results: The number of tru-cut biopsies performed during the nonpandemic and pandemic period was similar (1596, 1599). In the pandemic period, tru-cut biopsy histopathologic reports revealed that benign and high-risk cases decreased statistically, while invasive carcinoma cases increased by 1.9 (95% CI 1.6-2.2) times. During the pandemic period, US-guided BI-RADS 3 and BI-RADS 4a cases decreased statistically significantly, BBI-RADS 4b cases increased 1.4 (95% CI 1.1-2.2) times, BI-RADS 4c cases 1.7 (95% CI 1.2-2.2), BI-RADS 5 cases increased 2.1 (95% CI 1.4-3.1) times Conclusion: There was no significant change in tru-cut biopsy numbers compared to the period of the pandemic and the non-pandemic period. However, the stage of the cancers captured during the period of the pandemic was higher.

PDF

___

1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433.
2. Center for Systems Science and Engineering at Johns Hopkins. COVID-19 Dashboard. Coronavirus Resource Center. 2022. https:// coronavirus.jhu.edu/map.html. (Accessed 5.4.2022).
3. T.C. Sağlık Bakanlığı. COVID-19 bilgilendirme platformu. https://covid19.saglik.gov.tr/. (Accessed 5.4.2022)
4. Pediconi F, Galati F, Bernardi D, Belli P, Brancato B, Calabrese M, et al. Breast imaging and cancer diagnosis during the COVID-19 pandemic: recommendations from the Italian college of breast radiologists by SIRM. Radiol Med. 2020;125:926-30.
5. Fuhrman GM, Cederbom GJ, Bolton JS, King TA, Duncan JL, Champaign JL, et al. Image-guided core- needle breast biopsy is an accurate technique to evaluate patients with nonpalpable imaging abnormalities. Ann Surg. 1998;227:932-9.
6. Liberman L. Clinical management issues in percutaneous core breast biopsy. Radiol Clin North Am. 2000;38:791-07.
7. Dillon MF, Hill AD, Quinn CM, O'Doherty A, McDermott EW, O'Higgins N. The accuracy of ultrasound, stereotactic, and clinical core biopsies in the diagnosis of breast cancer, with an analysis of false-negative cases. Ann Surg. 2005;242:701-07.
8. Bassett LW, Mahoney MC, Apple SK. Interventional breast imaging: current procedures and assessing for concordance with pathology. Radiol Clin North Am. 2007;45:881-94.
9. Youk JH, Kim EK, Kim MJ, Oh KK. Sonographically guided 14-gauge core needle biopsy of breast masses: a review of 2,420 cases with long-term follow-up. AJR Am J Roentgenol. 2008;190:202-07.
10. Rikabi A, Hussain S. Diagnostic usefulness of tru-cut biopsy in the diagnosis of breast lesions. Oman Med J. 2013;28:125-7.
11. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOCOBAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-24.
12. IJzerman M, Emery J. Is a delayed cancer diagnosis a consequence of covid-19?. 2020. Available at: https://pursuit.unimelb.edu.au/articles/is-a- delayedcancer-diagnosis-a-consequence-of-covid-19. Accessed September 9, 2020.
13. Kaufman HW, Chen Z, Niles J, Fesko Y. Changes in the number of US patients with newly identified cancer before and during the coronavirus disease 2019 (COVID-19) pandemic. JAMA Netw Open. 2020;3:e2017267.
14. Koca B, Yildirim M. Delay in breast cancer diagnosis and its clinical consequences during the coronavirus disease pandemic. J Surg Oncol. 2021;124:261-67.
15. Pinto D, Schmitt F. The role of breast fine-needle aspiration during and post-COVID-19 pandemic: A fast and safe alternative to needle core biopsy. Cytopathology. 2020;31:627-29.
16. Naidich JJ, Boltyenkov A, Wang JJ, Chusid J, Hughes D, Sanelli PC. Impact of the coronavirus disease 2019 (COVID-19) pandemic on imaging case volumes. J Am Coll Radiol. 2020;17:865-72.
17. Lowry KP, Bissell MCS, Miglioretti DL, Kerlikowske K, Alsheik N, Macarol T et al. Breast biopsy recommendations and breast cancers diagnosed during the COVID-19 pandemic. Radiology. 2022;303:287-94.
18. Naidich JJ, Boltyenkov A, Wang JJ, Chusid J, Hughes D, Sanelli PC. Impact of the coronavirus disease 2019 (COVID-19) pandemic on imaging case volumes. J Am Coll Radiol. 2020;17:865-72.